Covid 19 Research using Clinical Trials (Home Page)
Vitamin DWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (6)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug66 | Aspirin 81 mg Wiki | 0.58 |
| drug915 | Zinc Wiki | 0.58 |
| drug333 | HCQ & AZ Wiki | 0.58 |
| drug900 | Vitamin C Wiki | 0.26 |
| drug558 | No intervention Wiki | 0.20 |
| drug360 | Hydroxychloroquine Wiki | 0.07 |
Correlated MeSH Terms (7)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D014808 | Vitamin D Deficiency NIH | 0.58 |
| D004211 | Disseminated Intravascular Coagulation NIH | 0.33 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.08 |
| D003141 | Communicable Diseases NIH | 0.07 |
| D018352 | Coronavirus Infections NIH | 0.06 |
| D014777 | Virus Diseases NIH | 0.06 |
| D007239 | Infection NIH | 0.05 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There are 3 clinical trials
Clinical Trials
1 Effect of Vitamin D Administration on Prevention and Treatment of Mild Forms of Suspected Covid-19
The new outbreak of the SARS-CoV-2 coronavirus is causing an important pandemic affecting a large number of people all-over the world. Vitamin D is a hormone precursor produced by our own body with the help of sunlight which has an important role on adaptive immunity and cellular differentiation, maturation and proliferation of several immune cells. Reduced levels of vitamin D in calves were positioned as the main cause of bovine coronavirus infection in the past. Therefore, it seems plausible that the use of vitamin D as a nutritional ergogenic aid could be a potential intervention to fight against COVID-19 infected patients which remain asymptomatic or which have non-severe and severe symptoms. This study aims to investigate whether the use of vitamin D as an immune modulator agent induces significant improvements of health status and outcomes in non-severe symptomatic patients infected with COVID-19 as well as preventing COVID-19 health deterioration. We hypothesize that vitamin D will significantly improve hard endpoints related to COVID-19 deleterious consequences compared with a usual care control group.
NCT04334005 Patients Infected With COVID-19 Dietary Supplement: Vitamin D
Primary Outcomes
Measure: Composite of cumulative death (i.e. mortality) for all causes and for specific causes. Time: Through study completion, an average of 10 weeksSecondary Outcomes
Measure: Necessity of invasive assisted ventilation Time: Through study completion, an average of 10 weeksMeasure: Necessity of non-invasive assisted ventilation Time: Through study completion, an average of 10 weeks
Measure: Intensive care unit admission Time: Through study completion, an average of 10 weeks
Measure: Post-anesthesia care unit admission Time: Through study completion, an average of 10 weeks
Measure: Hospital admission Time: Through study completion, an average of 10 weeks
Measure: Medical consultation Time: Through study completion, an average of 10 weeks
Measure: Home care and isolation time Time: Through study completion, an average of 10 weeks
Measure: Bed rest time Time: Through study completion, an average of 10 weeks
Measure: symptoms' duration (i.e. cough, fever, nasal congestion, gastrointestinal symptoms, fatigue, anosmia, ageusia, diarrhea or alternative signs of COVID-19) Time: Through study completion, an average of 10 weeks
Description: It will be measure by questionnaire
Measure: Subjective perception of recovery Time: Through study completion, an average of 10 weeks2 An Open Label Phase II Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Symptoms
This is a Phase II interventional study testing whether treatment with hydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent symptoms of COVID-19
NCT04335084 COVID-19 Coronavirus Infection Sars-CoV2 Corona Virus Infection COVID Coronavirus Coronavirus-19 Coronavirus 19 Drug: Hydroxychloroquine Dietary Supplement: Vitamin C Dietary Supplement: Vitamin D Dietary Supplement: Zinc MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Virus Diseases
Primary Outcomes
Description: Any symptoms of COVID-19 will be recorded in a daily diary. Symptoms (including fever measured in degrees Fahrenheit, dry cough, productive cough, difficulty speaking, wheezing, dry mouth, headache, chest tightness, difficulty with exertion, shortness of breath, sore throat, malaise, and diarrhea) will be rated as not present, mild, moderate, or severe.
Measure: Prevention of COVID-19 symptoms as recorded in a daily diary Time: 24 weeksDescription: To assess the presence or absence of side effects (graded 1-5), and whether they are tolerable (grade 1-2). AE and SAE will be recorded.
Measure: Safety as determined by presence or absence of Adverse Events and Serious Adverse Events Time: 24 weeks3 The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations
Although the novel SARS-CoV-2 virus (COVD-19) is classified as an acute respiratory infection, emerging data show that morbidity and mortality are driven by disseminated intravascular coagulopathy. Untreated CAC leads to microangiopathic thromboses, causing multiple systems organ failure and consuming enormous healthcare resources. Identifying strategies to prevent CAC are therefore crucial to reducing COVID-19 hospitalization rates. The pathogenesis of CAC is unknown, but there are major overlaps between severe COVID-19 and vitamin D insufficiency (VDI). We hypothesize that VDI is a major underlying contributor to CAC. Preliminary data from severe COVID-19 patients in New Orleans support this hypothesis. The purpose of the proposed multi-center, prospective, randomized controlled trial is to test the hypothesis that low-risk, early treatment with aspirin and vitamin D in COVID-19 can mitigate the prothrombotic state and reduce hospitalization rates.
NCT04363840 COVID Vitamin D Deficiency Coagulopathy Disseminated Intravascular Coagulation Drug: Aspirin 81 mg Dietary Supplement: Vitamin D MeSH:Disseminated Intravascular Coagulation Vitamin D Deficiency
HPO:Disseminated intravascular coagulation Low levels of vitamin D
Primary Outcomes
Description: Hospitalization for COVID-19 symptoms
Measure: Hospitalization Time: 2 weeks
Related HPO nodes (Using clinical trials)
Primary Outcomes
Description: Hospitalization for COVID-19 symptoms
Measure: Hospitalization Time: 2 weeks